Connection

Eric Bartee to Oncolytic Virotherapy

Back to Details
This is a "connection" page, showing publications Eric Bartee has written about Oncolytic Virotherapy.
Eric Bartee
Connection Strength
3.044
Oncolytic Virotherapy
  1. TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy. J Immunother Cancer. 2022 05; 10(5).
    View in: PubMed
    Score: 0.819
  2. The use of oncolytic virotherapy in the neoadjuvant setting. J Immunother Cancer. 2022 04; 10(4).
    View in: PubMed
    Score: 0.814
  3. Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. J Immunother Cancer. 2019 01 16; 7(1):11.
    View in: PubMed
    Score: 0.652
  4. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Res. 2017 06 01; 77(11):2952-2963.
    View in: PubMed
    Score: 0.574
  5. Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leuk Res. 2012 May; 36(5):619-24.
    View in: PubMed
    Score: 0.101
  6. Cytokine determinants of viral tropism. Nat Rev Immunol. 2009 Sep; 9(9):645-55.
    View in: PubMed
    Score: 0.085
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.